Getgoal Duo 1

In the GetGoal-Duo-1 trial, both groups gained weight, but patients in the lixisenatide arm gained less than those in the control arm (0.3 kg versus 1.2 kg, respectively;.

Getgoal duo 1. Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients (GetGoal-O) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. The originality of GetGoal DUO 2 is the comparison between add-on of lixisenatide and active treatment (prandial insulin). Efficacy and safety of once-daily lixisenatide added on to titrated glargine plus oral agents in type 2 diabetes:.

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:. Riddle MC, Forst T, Aronson R, et al. In GetGoal Duo 1, lixisenatide in combination with insulin glargine achieved the primary study endpoint of significantly reducing HbA1c with a significant improvement in 2-hour post-prandial.

The GetGoal Duo-2 Trial. The GetGoal program started in May 08 and has enrolled more than 4,500 patients. A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

Again, as in the 4B, body weight and hypoglycemia incidence. Propensity Score Matched Analysis. The GetGoal Duo 1 study evaluated once-daily lixisenatide added on to titrated glargine plus oral agents in type 2 diabetes.

In the GetGoal Duo 1, randomized, double-blind, multicenter study, 8 insulin-naïve patients were treated with insulin glargine (Lantus), which was titrated to reach a target fasting plasma glucose (FPG) of 80-100 mg/dL for a 12-week run-in phase period. Riddle MC, Forst T, Aronson R, Sauque-Reyna L, Souhami E, Silvestre L, Ping L, Rosenstock J. The GetGoal-Duo 1 study ePoster # 807 Session:.

OBJECTIVE To provide evidence-based options on how to intensify basal insulin, we explored head-to-head prandial interventions in overweight patients with type 2 diabetes inadequately controlled on basal insulin glargine with or without 1–3 oral antidiabetic agents (OADs). Patients in GetGoal-Duo 1 were from 25 countries and were inadequately controlled (HbA1c 53–86 mmol/mol 7.0–10.0%) on existing OAD therapy. Change in 2-h PPG and glucose.

Plain language summary available for this article. These patients were on existing basal insulin therapy with or without a SU. PS 063 GLP-1 based therapies Berlin 12 Poster Hall 3.

The abstract is titled:. To date, GetGoal-X, GetGoal-L, GetGoal-L Asia, GetGoal-Mono, GetGoal-S, GetGoal-F1 and GetGoal Duo 1 (also known as EFC*) have reported positive top-line results supporting potential efficacy and safety for lixisenatide. Like in 4B, in GetGoal DUO 2 the A1C decreased to similar values with lixisenatide or glulisine 1/d (~7.2%), or glulisine 3/d (~7.0%).

For Type 2 diabetes patients treated with basal. GetGoal Duo 1 and GetGoal-L both achieved the primary efficacy endpoint of HbA1c improvement with an associated significant reduction in PPG. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:.

A 24- week, Randomized, Placebo-Controlled Study (GetGoal Duo 1).” Diabetes Care 36.9 (13):. GetGoal-M, GetGoal-S) or in combination with basal insulin (GetGoal-L, GetGoal-Duo-1 and GetGoal-L-Asia). Rosenstock J, Forst T, Aronson R, et al.

Sanofi announced positive results from its Phase 3, GetGoal Duo 1 study of Lyxumia (lixisenatide) in combination with Lantus (insulin glargine;. Epub 16 May 23. Six randomized, placebo-controlled studies of lixisenatide µg once daily were included in this analysis:.

Sanofi) and OADs. A two-step dosage increase was used with both placebo and lixisenatide (10 μg for 1 week, 15 μg for 1 week, and then -μg maintenance dosage if tolerated), with injections self-administered by participants ≤1 h before breakfast. A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

Once-daily lixisenatide added on to consistently titrated insulin glargine plus oral agents in type 2 diabetes:. To conduct two exploratory analyses to compare indirectly the efficacy and safety of simultaneous administration of insulin glargine 100 U (iGlar) and the glucagon-like peptide-1 receptor agonist (GLP-1RA) lixisenatide (Lixi) as a single-pen, titratable, fixed-ratio combination (iGlarLixi LixiLan trials) vs sequential administration of iGlar + Lixi (GetGoal Duo trials) in people with. Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients (GetGoal-Duo-2) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

The GetGoal Duo-2 Evidence-Based Trial (NCT). The GetGoal program was initiated in May 08. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:.

Lixisenatide improved HbA1c, weight with standard GLP-1 safety profile PHILADELPHIA — Once-daily lixisenatide, an investigational GLP-1 agonist, was associated with significant HbA1c. "During a 12-week run-in phase, 8 insulin-naive patients were. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:.

October 12 12:00 - 13:00. 21 – 26 The GetGoal-X trial, which compared lixisenatide with twice-daily exenatide, resulted in weight loss of 2.96 kg and 3.98 kg, respectively. GetGoal Duo 1 was a randomized, double-blind, multicenter study assessing the efficacy and safety of lixisenatide compared to placebo in combination with Lantus (insulin glargine;.

"The results from the GetGoal Duo-2 study reconfirm the therapeutic benefits of Lyxumia(R) as a novel prandial GLP-1 agonist. A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). During the 12-week run-in phase, 8 insulin-naive patients were treated with insulin glargine, which was titrated to reach a target fasting.

Patients were randomized to receive lixisenatide or placebo 1:1 in GetGoal-Duo1 and GetGoal-L-Asia, and 2:1 in GetGoal-L. Riddle MC, Forst T, Aronson R et al. NCT (GetGoal Duo-2 trial).

Riddle, Mattew C.et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:. Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes:.

Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes:. Prandial Options to Advance Basal Insulin Glargine Therapy:. Sanofi) for the treatment of patients with type 2.

The trials were conducted between July 08 and August 11 across 25 countries (the number of countries and enrolment/completion dates varied by trial). Patients in GetGoal-Duo 1 were from 25 countries and were inadequately controlled (HbA1c 53–86 mmol/mol 7.0–10.0%) on existing OAD therapy. Riddle MC, Forst T, Aronson R, et al.

Duo is the highest quality 1 video calling app. If present, SU therapy was discontinued, and patients were initiated on basal insulin therapy with or without MET or a TZD during the run-in phase. So far, GetGoal-X, GetGoal-L, GetGoal-L Asia, GetGoal-Mono, GetGoal-S, GetGoal-F1 and GetGoal Duo 1 have reported positive top-line results.

Results showed that lixisenatide caused mild and transient nausea and vomiting, the most common adverse events, and a limited additional or comparable risk of hypoglycemia. Therefore, propensity score matching was used to indirectly compare simultaneous administration of iGlarLixi in the LixiLan-O trial (n=469) with sequential therapy, starting with initial insulin glargine 100 U/mL therapy for 12 weeks, followed by addition of lixisenatide in the GetGoal Duo-1 trial in patients with Type 2 diabetes mellitus who. Presented at the 72nd Scientific Sessions of the American Diabetes Association, Philadelphia PA, 8-12 June 12 (Abstract 62-OR).

-1 0 1 GetGoal-L1 GetGoal-L Asia2 GetGoal-Duo 13 e ) ~16.0 (2 mg/dL) 17.8 (3.4 mg/dL) ~13.0 (234 mg/dL) Baseline PPG Lixisenatide Added to Background Insulin:. Adjustment of dosage of insulin glargine. Lixisenatide activates the GLP-1 receptor and thereby exercises the range of physiological effects generated by GLP-1, which consist of increased insulin secretion, inhibition of glucagon secretion, and decreased gastrointestinal motility alongside the promotion of.

Lantus(R) is the No.1 leading basal insulin product in the world, and the results from GetGoal Duo 1 show that adding lixisenatide to treatment with Lantus(R) can offer significant benefits to patients." "Lixisenatide is a promising new GLP-1 agonist with a mode of action which complements that of basal insulin. MC Riddle, T Forst, R Aronson, et al.Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:. The GetGoal Duo-1 trial was the first study to assess the efficacy of lixisenatide in combination with optimally titrated basal insulin in patientswith type2 diabe-tesuncontrolledonOADswhowerenewly initiatinginsulinglargine.Signi ficantreduc-tions in HbA 1c to 7% (53 mmol/mol) and marked PPG reductions were achieved.

Lixisenatide as monotherapy (GetGoal-Mono), as add-on to oral antidiabetic drugs (OADs;. After a 12-week run-in phase in which insulin glargine was initiated, patients with A1C ≥7% were randomized to μg lixisenatide ( n = 223) or placebo ( n = 223) for 24 weeks while continuing on insulin glargine. GetGoal DUO 2 follows the studies GetGoal-L and GetGoal DUO 1 , which have both explored the efficacy and safety of once-a-day add-on of lixisenatide to basal insulin at fixed dose , or to insulin glargine with continuing titration as compared to placebo.

Advancing Basal Insulin Glargine with Prandial Lixisenatide QD vs Insulin Glulisine QD or TID in T2DM:. Further results are expected in 12. “Adding Once – Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine:.

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:. A 24-week, randomized, placebo-controlled study. RIDDLE THOMAS FORST RONNIE ARONSON FRCPC FACE LEOBARDO SAUQUE-REYNA ELISABETH SOUHAMI LOUISE SILVESTRE LIN PING JULIO ROSENSTOCK A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1) OBJECTIVEdWhen oral therapy for type 2 diabetes is ineffective, adding basal insulin improves glycemic control.

Patients in GetGoal-L Asia were from Japan, Republic of Korea, Taiwan, and the Philippines. In conclusion, 1) GLP-1-(7-36) amide or -(7-37) inhibits gastric emptying also in normal subjects, 2) physiological doses (0.4 pmol.kg-1.min-1) still have a significant effect, 3) despite the. The glucagon-like peptide (GLP)-1 receptor agonist lixisenatide (Lyxumia®) was approved for marketing by the European Medicines Agency in February 13 and has been evaluated in a clinical study program called GetGoal.

GetGoal Duo 1 is a randomized, double-blind, multicenter study, assessing the efficacy and safety of lixisenatide, compared to placebo, in combination with insulin glargine and OADs (mostly metformin). Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:. A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). The GetGoal-Duo 1 study assessed the complementary action of lixisenatide and insulin glargine in patients with type 2 diabetes failing on oral antidiabetes medication. Secondary Endpoints Change in 2-hr PPG Change in Body Weight.

A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

It’s free, simple and works on Android phones, iPhones, tablets, computers, and smart displays, like the Google Nest Hub Max. A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine:.

GETGOAL GLP-1 agonist AVE0010 in patients with type 2 diabetes mellitus for glycaemic control and safety evaluation (lixisenatide, µg once daily), GLP-1 RA glucagon-like peptide-1 receptor agonist,. In GetGoal DUO 2, the head-to-head comparison was between lixisenatide 1/d vs glulisine either 1/d (at the main meal, basal-plus) or 3/d (basal-bolus). GETGOAL-L-Asia GETGOAL-Duo-1 Cardiovascular outcome trials for GLP-1 RAs.